Last Week's Healthcare Sector Saw 24 Financing Deals Involving 9 Chinese Pharma Companies Filing IPO Prospectuses

　　【Pharmaceutical Network Industry DynamicsAccording to data statistics, last week (January 22 - January 28), the medical and health field disclosed 24 financing events, with a total financing amount of approximately 18.655 billion yuan. Among these 24 financing events, 9 involved domestic companies and 15 involved foreign companies. Specifically, in China's medical and health sector, 1 company was acquired, 8 companies received investments, and the total financing amount was about 692 million yuan.
 

According to reports, last week New Alliance Capital completed the payment of 70 million RMB in investment to Dr. Mayson, bringing the total amount raised in Dr. Mayson's D-round financing to 370 million RMB. As a provider of medical artificial intelligence solutions in China, Dr. Mayson is committed to using CDSS technology to improve medical quality and safeguard patient safety. As of the end of 2023, Dr. Mayson's medical artificial intelligence solutions have been implemented in nearly 800 hospitals, including 42 hospitals from the Fudan TOP100 list, building intelligent protection for medical quality and patient safety.
 

Last week, Boyue Biotech announced that it had received strategic investment from Minsheng Pharmaceuticals and Ambition Pharmaceuticals, with the investment amount undisclosed. Data shows that Boyue Biotech, established in 2010, is a technology innovation enterprise focusing on innovative drug research and development, high-end generic drug research and development, and consistency evaluation, providing one-stop services for drug development and registration.
 

Last week, Huhu Health received an investment of 12 million yuan from Shanghai Mingyue Industrial Co., Ltd. and Mingyue Lens Co., Ltd. The company, headquartered in Zhejiang Province, China, is a medical health service provider specializing in vision protection.
 

Last week, DPM completed a C round financing of 200 million RMB, with investors including Zhiyi Daohe, Yunqi Investment, and Huiding Investment. Data shows that DPM is a provider of high-end medical equipment and innovative medical technology, focusing on the research and development of precise optical molecular imaging products and technologies during surgery, offering multi-faceted intraoperative molecular image navigation solutions and services.
 

Last week, REUNION announced the successful completion of a nearly RMB 100 million Series B financing round. This round was led by DCP Capital, with over-subscription from existing shareholders Qiming Venture Partners and Guoxin Innovation Equity, while Huaxing Capital served as the exclusive financial advisor. The proceeds will mainly be used to advance the registration and market promotion of its lead product, accelerate clinical trials across multiple product lines, and expand innovative pipelines. Data shows that REUNION is a medical hydrogel technology platform developing a robust portfolio of global First/Best-In-Class products, providing systematic solutions such as tumor radiotherapy protection, tumor embolization, and tissue filling to address urgent clinical needs.
 

Last week, Anlong successfully completed a multi-million-dollar A+ round of financing. This round was jointly invested by Tai Kun Fund and Shun Cheng Industry Investment Management Fund, and will be used to advance the clinical trials of Anlong's AAV gene therapy product AL-001 and the research and development of small nucleic acid innovative drugs. Anlong is a gene therapy drug developer whose self-developed AAV gene therapy drug AL-001 ophthalmic injection received CDE clinical trial approval in April 2023 and successfully completed the dosing of its first subject in July 2023. The indication for this product is age-related macular degeneration (wet form).
 

Last week, Inscope Medical announced the completion of an over 100-million-yuan Series A strategic financing round, led by Weigao Songyuan Fund with Longpan Investment participating. Following this round of financing, Inscope Medical will further expand its rigid endoscope and disposable endoscope product portfolio and accelerate the global layout of its sales channels. Data shows that Inscope Medical is a medical device company engaged in the research, production, and sales of high-end medical endoscopic systems and related innovative products.
 

Last week, U-Art Biotech announced the completion of an angel round of financing worth tens of millions of RMB. This round of financing was led by JAFCO Asia (Shanghai) Equity Investment Management Co., Ltd., with participation from Shanghai Dongfeng Ruichuang.Biological ReagentsCo., Ltd. follows the investment. Data shows that Uyir Bio is a serum-free culture medium R&D producer, mainly engaged in the R&D and production of serum-free culture media, cosmetic raw material R&D, etc.
 

Last week, in addition to the above eight pharmaceutical companies announcing the completion of financing, one company was acquired. Quanyi Health announced last week the completion of the acquisition of Zhejiang Ruitang, involving more than 600 pharmacies.
 

Disclaimer: In any case, the information or opinions expressed in this article do not constitute investment advice for any person.